ATAGI 关于 12-17 岁青少年使用 Novavax 疫苗的建议

ATAGI have now recommended that adolescents aged 12-17 years can receive the Novavax COVID-19 vaccine for their primary course of COVID-19 vaccination. This recommendation provides another vaccine brand option, in addition to Pfizer and Moderna, for individuals in this age group. 

A Novavax primary schedule consists of 2 doses, administered 8 weeks apart. Those with 严重的免疫功能低下 should receive 3 doses. 

Whilst Novavax is not currently registered for use as a booster dose in adolescents aged 12-17 years, ATAGI advises that it may be used for this purpose, when Pfizer is not suitable for that person.

To read the recommendations in full please follow the link below.  
ATAGI recommendations on the use of the Novavax vaccine for adolescents aged 12-17 years.

疫苗工作 GAVI:过去和现在有关猴痘的五张图表

Despite the first cases of monkeypox infection in humans being reported in the 1970’s, previous outbreaks of disease have been relatively small compared with the international outbreak we are currently experiencing. Human to human transmission has been historically uncommon with cases limited to smaller geographical regions. Current rates of infection, with extensive human to human transmission and wide global spread has led this outbreak to be a very unique scenario.

The following article uses the latest data to explore the current rates of infection across different demographics and regions, the impact of pre-existing medical conditions, as well as vaccine access and severity of disease.

To read the article in full, click on the link below.
疫苗工作 GAVI:过去和现在有关猴痘的五张图表 

To view our reference page on monkeypox, click on the link below. 

VACSIG 网络研讨会录音现已提供

A webinar recording is now available from the recent Vaccination Special Interest Group (VACSIG) event on Wednesday 17 August.  The topic for the webinar was Monkeypox & smallpox vaccines: an Australian perspective, and featured a panel of expert speakers including MVEC’s A/Prof Nigel Crawford. 
To view the recording, please click on the link below. 
VACSIG Webinar 17 August

MVEC 免疫技能研讨会现已开放报名 – 2022 年 11 月 25 日星期五

MVEC are pleased to announce that registrations for our 免疫技能研讨会 taking place on Friday 25 November are now open.  

The full day interactive, face to face workshop is MVEC’s newest education opportunity designed to provide education and upskilling in the principles and processes of managing: 

  • 有效的疫苗沟通 
  • 错误预防和管理 
  • 过敏反应和急性应激反应。 

Participants will hear from immunisation experts and have the opportunity to engage in simulated scenarios. 

The workshop will account for 12 nursing CPD hours and up to 24 points of CPD for pharmacist immunisers (including preparation and reading time). 

地点: The HELP Precinct, The HELP Precinct, 皇家儿童医院, 50 Flemington Road, Parkville
时间: 上午 8:30 至下午 4:30
成本: $290.00(含餐饮) 

Register for the Immunisation Skills Workshop now via the link below!
MVEC Immunisation Skills Workshop 

八月 CVU 迷你活动现已开放报名

MVEC’s next Clinical Vaccinology Update (CVU) mini event on COVID-19: infection and vaccines in children aged 6 months and over will take place virtually on Tuesday 30th August. This CVU mini will provide an update on: 

  • 针对 6 个月以上澳大利亚儿童的 COVID-19 疫苗建议 
  • 儿童 COVID-19 疫苗的安全性
  • COVID-19 vaccine rollout logistics

The event program and link to register will be available shortly via our Events page or via the link below. 

CVU mini: August 2022 


更新了 MVEC 免疫参考页面:儿童和青少年的 COVID-19 疫苗接种页面

MVEC’s COVID-19 vaccination in children and the adolescent reference page has been updated to include the current recommendations for children under 5 years of age. This resource details:  

  • Recommended COVID-19 vaccine schedule information for children and adolescents aged ≥ 6 months 
  • Information on the efficacy and side effects of COVID-19 vaccination in the paediatric population 
  • Links to current ATAGI COVID-19 vaccine recommendations in the various paediatric and adolescent age groups  


MVEC:儿童和青少年的 COVID-19 疫苗接种 

新的免疫参考页面 – 猴痘

猴痘是一种病毒性人畜共患病(一种从动物传播给人类的感染)。它是由属于 正痘病毒 genus (which also causes the variola virus responsible for smallpox disease and the vaccinia virus, which is used in smallpox vaccines). Since the eradication of smallpox in 1980, monkeypox has become the most important orthopoxvirus affecting humans, however, causes less severe disease than smallpox.  

The incubation period of monkeypox is usually 7-14 days, with initial symptoms of monkeypox including fever, headache, backache and muscle aches, fatigue and lymphadenopathy. Historically, smallpox vaccines have been used in the prevention of smallpox infection, however, they are also likely to be effective against monkeypox.  

There are two types of smallpox vaccines registered for use in Australia for the prevention of monkeypox, ACAM2000™ and JYNNEOS®.  

Our new reference page outlines symptoms, transmission routes, epidemiology, current vaccine recommendations and links to the latest resources. 

For further information, click on the link below:

ATAGI 关于 5 岁以下儿童使用 COVID-19 疫苗的建议

ATAGI have now recommended COVID-19 vaccination for some children aged 6 months – 5 years. Eligible groups include those with severe immunocompromise, a disability with severe or complex health needs, or those with multiple/complex health conditions that increase the risk of severe COVID-19 disease.  

A paediatric formula of the Moderna COVID-19 vaccine has been approved by the TGA in this age group for children in the groups mentioned above. A primary two-dose schedule, 8 weeks apart is recommended, with the dose being 25mcg. Children in this age group with severe immunocompromise are recommended to complete a 3-dose primary schedule.  

基于一系列因素,ATAGI 目前不建议不属于上述类别的 6 个月至 5 岁儿童接种 COVID 疫苗。  

随着替代品牌或变体 COVID-19 疫苗在这个年龄段可用,或者如果出现流行病学变化(例如出现新的令人担忧的变体),建议可能会发生变化。  

To read the recommendations in full please follow the link below.  

ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years

COVID-19 疫苗对超过 200,000 名澳大利亚儿童的安全性:来自 AusVaxSafety 的令人放心的数据

New AusVaxSafety research which analysed 392,268 survey responses via AusVaxSafety’s national active safety surveillance system between July 2021 and May 2022, has found that Australian children aged 5-15 years report fewer side effects in the days following mRNA COVID-19 vaccination than those reported in clinical trials and published safety data.

Importantly, fever was reported low in the youngest age group, comparable to that seen following annual influenza vaccination. Additionally, there were also no self-reported cases of myocarditis and pericarditis identified in the study.

AusVaxSafety will commence surveillance in children aged 6 months to 5 years once COVID-19 vaccines become available in this age group.

To access the research in full, click on the link below. 

Safety of COVID-19 vaccines in >200,000 Aussie kids: reassuring data from

Flinders University Alumni publication featuring A/Prof Nigel Crawford: Providing the vital boost for us to fight COVID-19

MVEC’s Associate Professor Nigel Crawford was featured in the Flinders University College of Medicine and Public Health Alumni magazine regarding his significant contribution to Australia’s COVID-19 vaccine rollout. As the current chair of the Australian Technical Advisory Group for Immunisation (ATAGI), Nigel discusses his role in steering Australia’s uptake of COVID-19 vaccines, including effective communication and the ability to remain flexible when responding to and adapting vaccine advice for the general public. 

To read the full article, follow the link below.

Flinders University Alumni publication featuring A/Prof Nigel Crawford: Providing the vital boost for us to fight COVID-19